HEK293 NEK7-HiBiT Knock In cell line

HEK293 NEK7-HibiT Knock In Cell Line

Item	Cat#	Price
Stable Cell Line	SNB-H-0006A	Inquiry
Compound Test Services	CT-001	$1,950 per 384w plate *(Up To 16 cpds Dose)*

Ask For A Custom Quote

Product Description

NEK7 (NIMA-related kinase 7) is a serine/threonine kinase that regulates mitosis and cytokinesis and is essential for NLRP3 inflammasome activation. It is overexpressed in several cancers and linked to poor prognosis. These roles make NEK7 a promising therapeutic target for NEK7-dependent cancers and NLRP3-driven inflammatory diseases.

ScreeningBio's HEK293 NEK7-HiBiT Knock In cell line enables quantitative measurement of target protein levels in a single assay. In this system, the HiBiT-tagged NEK7 expressed from the endogenous locus complements with exogenously added LgBiT to generate a luminescent signal directly proportional to the amount of NEK7 present, allowing accurate and reproducible quantification of NEK7 degradation.

Product Specifications

Target Type	NIMA (never in mitosis gene a)- related kinase
Species	Human
HGNC Symbol	NEK7
Accession Number	NM_133494.3
Parental Line	HEK293
Lot#	See Vial
Storage	Liquid Nitrogen

Data

HEK293 NEK7-HiBiT Knock In Assay. HEK293 NEK7-HiBiT Knock In cells were treated with the NEK7 degrader-1. Non-linear regression was used to plot activity changes vs. [Compound, M] and DC50 values were determined using GraphPad Prism software. — **HEK293 NEK7-HiBiT Knock In Assay.** HEK293 NEK7-HiBiT Knock In cells were treated with the NEK7 degrader-1. Non-linear regression was used to plot activity changes vs. [Compound, M] and DC₅₀ values were determined using GraphPad Prism software.

**HEK293 NEK7-HibiT Knock In Assay Sanger Sequencing Results.**

Target Background

NEK7 (NIMA-related kinase 7) is a serine/threonine kinase that regulates mitosis and cytokinesis and is essential for NLRP3 inflammasome activation. It is overexpressed in several cancers and linked to poor prognosis.

These roles make NEK7 a promising therapeutic target for NEK7-dependent cancers and NLRP3-driven inflammatory diseases.